Sitagliptin, added to the usual treatment of type 2 diabetes, does not increase the risk of major cardiovascular episodes or hospitalizations, according to a study promoted by MSD.
The Cardiovascular Security Study Tecos for the Evaluation of Cardiovascular Results with Sitagliptin, carried out with a sample of 14,671 patients from 38 countries with at least 50 years suffering.
The head of the Endocrinology and Nutrition Service of the University Hospitals Quirón Madrid and a researcher of the Cardiovascular Security Study Tecos, Esteban Jodar, has assured that "the Tecos study is very reassuring, since it clears doubts about the cardiovascular safety of a drug use drugIn people with type 2 diabetes such as Sitagliptin, whose safety and efficacy profile are known both for their clinical development studies and for their wide use in daily practice. "
The research was presented in the 75th edition of the scientific sessions of the American Diabetes Association, held on June 8 in Boston (USA), and has been published in the 'New England Journal of Medicine'.
"For some years, the regulatory authorities demand that in this area drugs, in addition to showing their efficacy and safety in clinical development tests, also demonstrate to be safe at the cardiovascular level in patients with diabetes and high risk of cardiovascular problems.", said Fuck.
More than 600,000 Madrid have type 2 diabetes, although approximately 200,000 are unknown, according to the Federation of Spanish Diabetics (Fede).The main cause of morbidity and mortality in people with type 2 diabetes mellitus is cardiovascular disease and patients in this pathology have a risk of 2 to 4 times higher of developing cardiovascular disease with respect to the population without diabetes, hence the importance ofsafe and effective drugs that do not increase the chances of suffering cardiovascular problems.